

## **NEUREN PHARMACEUTICALS LIMITED MODERN SLAVERY STATEMENT 2023**

### **Introduction**

Neuren Pharmaceuticals Limited ACN 111 496 130 (Neuren) is a public company, incorporated in New Zealand and listed on the Australian Securities Exchange (ASX:NEU). Neuren's registered office is Suite 201, 697 Burke Rd, Camberwell, Victoria, 3124, Australia.

Neuren has a subsidiary in the United States, Neuren Pharmaceuticals, Inc.

This is Neuren's first modern slavery statement, and it sets out the actions Neuren has taken to assess and address modern slavery risk in our operations and supply chains during the year ended 31 December 2023.

### **Operations and supply chains**

Neuren's operations are research and development of new drug therapies for highly debilitating neurodevelopmental disorders that emerge in early childhood and are characterised by impaired connections and signalling between brain cells.

Neuren is not involved in large-scale manufacturing and marketing and distribution of pharmaceutical products.

Neuren's supply chains include:

- Goods and services provided to deliver our research and development activities, such as clinical trial support, expert regulatory, research and laboratory services.
- Goods and services provided to manufacture, store and deliver our exploratory drug products required for our clinical trial research and development programs, such as pharmaceuticals ingredients, packaging, transportation and warehousing.
- Goods and services provided as support for corporate services, including IT, finance, tax, legal and human resources.

### **Risks of modern slavery practices in operations and supply chains**

During the reporting period, we reviewed our operations and supply chains to identify and assess modern slavery risk and have assessed the following key areas.

#### Workforce

We acknowledge some countries are associated with higher risks of modern slavery, due to poor governance, weak rule of law, conflict, migrant flows and socio-economic factors like poverty.

Neuren's direct operations and geographic footprint are in Australia and the United States. We consider the risk of modern slavery in our directly employed workforce to be low, due to the regulated nature of the pharmaceutical industry, our employees being highly educated or skilled and the small size of our workforce. Neuren's small workforce of 24 people all work from home and no office or other facility is maintained.

#### Suppliers

The risk of modern slavery increases as we engage with third parties.

We recognise the potential risk of Neuren contributing to Modern Slavery as a result of the geographic location of contract manufacturers or suppliers of ingredients and components used to manufacture the exploratory drug product and conduct clinical research activities and laboratory services. Most of Neuren's suppliers of these goods and services are based in the regions of North America, Western Europe and Asia. Within Asia, Neuren's suppliers are located in China and Neuren recognises the increased risk of state-imposed forced labour in China. Whilst no sector is immune to modern slavery risk, there are generally higher modern slavery risks in the manufacture of electronics, garments and consumables which are not procured by Neuren.

Neuren requires third party manufacturers to be compliant with the US Food and Drug Administration (FDA) Good Manufacturing Practice (GMP) procedures.

### **Actions taken to assess and address modern slavery risks**

Actions taken during this first reporting period to assess modern slavery risks include:

- undertaking a high-level risk assessment of Neuren's operations and supply chain;
- visiting supplier facilities in North America and Western Europe during the reporting period; and
- undertaking internal audits and commissioned third party audits of several suppliers.

Neuren intends to increase its governance around modern slavery by developing a framework around the key areas: governance, risk assessment, monitoring, reporting and oversight.

Neuren has a Whistleblower Policy, which is published on its website and provides an avenue for raising and addressing any concerns or risks, including in our supply chain.

### **Effectiveness of the actions taken**

During this reporting period, Neuren focused on gaining an understanding of our modern slavery risks and how identifying the risks that may be present in our operations and supply chains. During these early stages, we recognise that our review and assessment of our actions to identify and address modern slavery risks will be an ongoing process. We will continue to work on developing frameworks and processes to ensure we can review the effectiveness of actions we take to assess and address modern slavery risks in our operations and supply chains.

### **Consultation and approval**

We consulted the relevant companies we own or control in the development of this Modern Slavery Statement.

This Modern Slavery Statement is made in accordance with the Modern Slavery Act 2018 (Cth). This statement was approved by the Board of Directors of Neuren Pharmaceuticals Limited in their capacity as principal governing body of Neuren Pharmaceuticals on 1 July 2024 and signed on its behalf by:



**Patrick Davies**  
**Chair of Neuren Pharmaceuticals Limited**